AL Granstrom et al. JPGN 2018; 66: 398-401. Using a nationwide Swedish registry, the authors determined that patients with a Hirschsprung disease had an increased risk of receiving a diagnosis of IBD (OR 4.99). In total 20 of 739 HD patients, developed IBD.
T Card et al. Inflamm Bowel Dis 2018; 24: 953-9. This article questions the ‘what is the risk of progressive multifocal leukoencephalopathy ..with vedolizumab? The authors are not certain. But they state that after reviewing 54,619 patient-years “there have been no cases of PML reported in association with vedolizumab use.”
LCT Buer et al. Inflamm Bowel Dis 2018; 24: 997-1004. This case report of 10 patients describes combination therapy with anti-TNF therapy with vedolizumab. “At the end of follow-up, all patients were in clinical remission, and 8 patients could discontinue anti-TNF treatment.”
OJ Adedokun et al. Gastroenterol 2018; 154: 1660-71. This study examined pharmocokinetics and response of ustekinumab in patients with Crohn’s disease from 701 patients in phase 3 studies.. “Trough concentrations was approximately threefold higher in patients given ustekinumab at 8-week intervals compared with 12-week intervals…Trough concentrations of 0.8 (or even up to 1.4 mcg/mL) or greater were associated with maintenance of clinical remission.” Also, “concentrations of ustekinumab did not seem to be affected by cotreatment with immunomodulators.”